On September 21, METIS TECHBIO-P rose 5.52% in regular trading, trading at HK$17.95 per share, with turnover of approximately HK$36.13 million. The stock extended its rally after surging over 14% in the prior session, supported by multiple converging catalysts.

On the policy front, the official release of China's 15th Five-Year Plan has lifted AI healthcare concept stocks broadly, with METIS TECHBIO-P emerging as a sector leader. Meanwhile, the company's recently announced joint venture with Zhaoyan Bio to establish ZhaoTai Zhiyao — a platform dedicated to mRNA drug innovation R&D and industrialized manufacturing — continues to generate sustained market interest. Under the agreement, METIS TECHBIO-P contributes upstream AI-driven mRNA sequence design and nano-delivery capabilities through its proprietary NanoForge platform, which has achieved targeted delivery to eight key human organs and tissues. Additionally, the stock benefited from its recent inclusion in the Stock Connect program in early September, unlocking southbound capital flows, and a strategic partnership with Luye Pharma as its first AI drug delivery collaborator.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)